Pemetrexed

Generic Name
Pemetrexed
Brand Names
Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
Drug Type
Small Molecule
Chemical Formula
C20H21N5O6
CAS Number
137281-23-3
Unique Ingredient Identifier
04Q9AIZ7NO
Background

Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...

Indication

Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions
Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
Associated Therapies
Monotherapy

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

First Posted Date
2023-08-14
Last Posted Date
2023-08-14
Lead Sponsor
Akeso
Target Recruit Count
642
Registration Number
NCT05990127
Locations
πŸ‡¨πŸ‡³

The Second Xiangya Hospital, Central South University, Changsha, Hunan, China

πŸ‡¨πŸ‡³

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

πŸ‡¨πŸ‡³

Cancer hospital, Chinese academy of medical sciences and Peking union medical college, Beijing, Beijing, China

and more 59 locations

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

First Posted Date
2023-08-09
Last Posted Date
2024-12-13
Lead Sponsor
AstraZeneca
Target Recruit Count
900
Registration Number
NCT05984277
Locations
πŸ‡¬πŸ‡§

Research Site, Truro, United Kingdom

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

First Posted Date
2023-07-17
Last Posted Date
2023-12-13
Lead Sponsor
SCRI Development Innovations, LLC
Registration Number
NCT05948462
Locations
πŸ‡ΊπŸ‡Έ

Texas Oncology, Dallas, Texas, United States

πŸ‡ΊπŸ‡Έ

Messino Cancer Center, Asheville, North Carolina, United States

πŸ‡ΊπŸ‡Έ

Tennessee Oncology, Nashville, Tennessee, United States

and more 2 locations

A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

First Posted Date
2023-06-26
Last Posted Date
2023-06-27
Lead Sponsor
Biotheus Inc.
Target Recruit Count
55
Registration Number
NCT05918107
Locations
πŸ‡¨πŸ‡³

Jilin Provincial Tumor Hospital, Changchun, China

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

First Posted Date
2023-06-22
Last Posted Date
2024-08-19
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
24
Registration Number
NCT05911308
Locations
πŸ‡ΊπŸ‡Έ

Moffitt Cancer Center, Tampa, Florida, United States

πŸ‡ΊπŸ‡Έ

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

πŸ‡ΊπŸ‡Έ

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer

First Posted Date
2023-06-15
Last Posted Date
2024-03-06
Lead Sponsor
Akeso
Target Recruit Count
233
Registration Number
NCT05904379
Locations
πŸ‡¨πŸ‡³

Shanghai Pulmonary Hospital, Shanghai, China

πŸ‡¨πŸ‡³

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

First Posted Date
2023-05-23
Last Posted Date
2023-08-08
Lead Sponsor
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Target Recruit Count
356
Registration Number
NCT05870319
Locations
πŸ‡¨πŸ‡³

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

First Posted Date
2023-04-10
Last Posted Date
2024-05-01
Lead Sponsor
Taipei Veterans General Hospital, Taiwan
Target Recruit Count
23
Registration Number
NCT05805631

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

First Posted Date
2023-04-05
Last Posted Date
2023-04-05
Lead Sponsor
Guangdong Provincial People's Hospital
Target Recruit Count
30
Registration Number
NCT05800340
Locations
πŸ‡¨πŸ‡³

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guanzhou, Guangdong, China

Β© Copyright 2024. All Rights Reserved by MedPath